Allspring Global Investments Holdings LLC Buys 47,166 Shares of DaVita Inc. (NYSE:DVA)

Allspring Global Investments Holdings LLC grew its stake in shares of DaVita Inc. (NYSE:DVA) by 82.8% in the fourth quarter, Holdings Channel reports. The fund owned 104,115 shares of the company’s stock after acquiring an additional 47,166 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in DaVita were worth $10,907,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Raymond James & Associates lifted its stake in shares of DaVita by 4.0% during the 1st quarter. Raymond James & Associates now owns 22,651 shares of the company’s stock valued at $2,562,000 after buying an additional 865 shares in the last quarter. American Century Companies Inc. lifted its stake in shares of DaVita by 37.4% during the 1st quarter. American Century Companies Inc. now owns 6,555 shares of the company’s stock valued at $741,000 after buying an additional 1,785 shares in the last quarter. US Bancorp DE lifted its stake in shares of DaVita by 63.6% during the 1st quarter. US Bancorp DE now owns 2,998 shares of the company’s stock valued at $338,000 after buying an additional 1,166 shares in the last quarter. Cambridge Investment Research Advisors Inc. lifted its stake in shares of DaVita by 7.3% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 3,551 shares of the company’s stock valued at $402,000 after buying an additional 242 shares in the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund lifted its stake in shares of DaVita by 847.8% during the 1st quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,090 shares of the company’s stock valued at $123,000 after buying an additional 975 shares in the last quarter. 90.12% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, insider James O. Hearty sold 26,164 shares of the firm’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $119.64, for a total value of $3,130,260.96. Following the completion of the sale, the insider now directly owns 20,264 shares of the company’s stock, valued at approximately $2,424,384.96. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In other news, insider James O. Hearty sold 26,164 shares of the firm’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $119.64, for a total value of $3,130,260.96. Following the completion of the sale, the insider now directly owns 20,264 shares of the company’s stock, valued at approximately $2,424,384.96. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Javier Rodriguez sold 67,603 shares of the firm’s stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $126.11, for a total transaction of $8,525,414.33. Following the completion of the sale, the chief executive officer now directly owns 488,697 shares of the company’s stock, valued at $61,629,578.67. The disclosure for this sale can be found here. Insiders have sold a total of 134,540 shares of company stock valued at $16,551,071 in the last quarter. Insiders own 1.40% of the company’s stock.

DaVita Stock Performance

DaVita stock opened at $129.83 on Wednesday. The firm’s fifty day moving average price is $129.69 and its 200-day moving average price is $108.53. The company has a debt-to-equity ratio of 6.65, a quick ratio of 1.13 and a current ratio of 1.19. The stock has a market cap of $11.39 billion, a P/E ratio of 17.54, a price-to-earnings-growth ratio of 1.16 and a beta of 1.04. DaVita Inc. has a fifty-two week low of $71.51 and a fifty-two week high of $141.54.

DaVita (NYSE:DVA) last released its earnings results on Tuesday, February 13th. The company reported $1.87 EPS for the quarter, beating the consensus estimate of $1.53 by $0.34. The company had revenue of $3.15 billion for the quarter, compared to analyst estimates of $3.01 billion. DaVita had a net margin of 5.70% and a return on equity of 64.42%. The firm’s quarterly revenue was up 7.8% compared to the same quarter last year. During the same quarter last year, the firm earned $1.11 EPS. On average, equities research analysts expect that DaVita Inc. will post 9.23 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently commented on DVA. UBS Group upped their price target on shares of DaVita from $113.00 to $134.00 and gave the company a “buy” rating in a research note on Wednesday, February 14th. StockNews.com cut shares of DaVita from a “strong-buy” rating to a “buy” rating in a research note on Tuesday. TheStreet upgraded shares of DaVita from a “c+” rating to a “b-” rating in a research note on Wednesday, February 7th. Truist Financial increased their target price on shares of DaVita from $130.00 to $135.00 and gave the stock a “hold” rating in a research note on Tuesday, February 20th. Finally, Barclays began coverage on shares of DaVita in a research note on Wednesday, March 6th. They issued an “equal weight” rating and a $133.00 target price on the stock. Two equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $118.50.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.